X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SF2a-TT15
Therapeutic Area: Infections and Infectious Diseases Product Name: SF2a-TT15
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Institut Pasteur
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The clinical study in healthy adults shows that the vaccine (SF2a-TT15) is well tolerated and immunogenic. Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RSVDG vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
The vaccine candidate was observed to trigger immunogenicity following nasal administration in healthy adults aged 18 to 50. Investigators also reported the candidate to be safe and well-tolerated.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
